ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Gulden Menderes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.